Analyst Ratings For AzurRx BioPharma Inc (NASDAQ:AZRX)
Today, HC Wainwright reiterated its Buy rating on AzurRx BioPharma Inc (NASDAQ:AZRX) with a price target of $8.00.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on AzurRx BioPharma Inc (NASDAQ:AZRX) is Buy with a consensus target price of $7.10 per share, a potential 253.23% upside.
Some recent analyst ratings include
- 2/21/2019-AzurRx BioPharma Inc (NASDAQ:AZRX) had its Buy rating reiterated by HC Wainwright with a $8.00 price target
- 1/25/2019-AzurRx BioPharma Inc (NASDAQ:AZRX) has coverage initiated with a Buy rating and $10.50 price target
- 10/17/2018-AzurRx BioPharma Inc (NASDAQ:AZRX) has coverage initiated with a Outperform ➝ Outperform rating and $6.00 price target
- On 12/31/2018 Edmund Burke Jr. Ross, Major Shareholder, bought 23,848 with an average share price of $1.12 per share and the total transaction amounting to $26,709.76.
- On 12/28/2018 Charles J Casamento, Director, bought 9,000 with an average share price of $1.41 per share and the total transaction amounting to $12,690.00.
- On 12/28/2018 Charles J Casamento, Director, bought 9,000 with an average share price of $1.41 per share and the total transaction amounting to $12,690.00.
- On 12/28/2018 Johan M Spoor, CEO, bought 38,583 with an average share price of $1.30 per share and the total transaction amounting to $50,157.90.
- On 12/28/2018 Maged Shenouda, CFO, bought 20,000 with an average share price of $1.31 per share and the total transaction amounting to $26,200.00.
- On 12/28/2018 Maged Shenouda, Insider, bought 20,000 with an average share price of $1.31 per share and the total transaction amounting to $26,200.00.
- On 12/27/2018 Edmund Burke Jr. Ross, Major Shareholder, bought 66,122 with an average share price of $1.16 per share and the total transaction amounting to $76,701.52.
About AzurRx BioPharma Inc (NASDAQ:AZRX)
AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
Recent Trading Activity for AzurRx BioPharma Inc (NASDAQ:AZRX)
Shares of AzurRx BioPharma Inc closed the previous trading session at 2,01 +0,31 18,24 % with 2.27 shares trading hands.